Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company – no impact on the consolidated financials

Hansa Biopharma AB announces that, in accordance with chapter 4, 6§ of the Swedish Annual Accounts Act and RFR 2, it has elected to recognize a write-up of SEK 1.430 billion in intangible assets in the statutory financial statements of the parent company Hansa Biopharma AB.